Ralimetinib dimesylate
Ralimetinib dimesylate (LY2228820 dimesylate) is an orally bioavailable, tri-substituted imidazole inhibitor of p38 MAPK. It has demonstrated potential anti-inflammatory and anti-cancer activity in preclinical in vitro and in vivo models, supporting research in oncology and inflammatory disease.
Product Specifications
CAS Number
862507-23-1
Product Name Alternative
Autophagy, Apoptosis, LY 2228820, LY 2228820 Dimesylate, LY-2228820, LY2228820 dimesylate, LY-2228820 Dimesylate, p38α, p38MAPK, p38 MAPK
Field of Research
Cell Biology, Signal Transduction
Purity
98.00% (May vary between batches)
Solubility
DMSO:27.5 mg/mL (44.88 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.26 mM)
Smiles
CS (O) (=O) =O.CS (O) (=O) =O.CC (C) (C) Cn1c (N) nc2ccc (nc12) -c1[nH]c (nc1-c1ccc (F) cc1) C (C) (C) C
Molecular Formula
C24H29FN6·2CH4O3S
Molecular Weight
612.74
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-Zebrafish SARS/SARS1 Antibody Picoband® Fluoro647 Conjugated
Recombinant Thioredoxin-interacting protein (Txnip)
Recombinant Thioredoxin-interacting protein (Txnip)
Recombinant Thioredoxin-interacting protein (Txnip)
Recombinant Thioredoxin-interacting protein (Txnip)